Urolithin A

Urolithin A

Evidence & Status

  • Moderate Evidence
  • Moderate

At a Glance

A gut-microbiota-derived metabolite and administered postbiotic studied for mitophagy and muscle-related biology. Human intervention evidence exists, but preclinical lifespan findings and short-term human outcomes do not establish human longevity benefit.

Plain English

Urolithin A can be made when gut bacteria process ellagitannins, but taking pomegranate or other precursor foods is not the same as receiving a defined Urolithin A exposure. Researchers have studied direct Urolithin A for safety, molecular markers, and some muscle outcomes. Animal lifespan findings and short-term human markers are not proof of longer human life or broad disease prevention.

Overview

Urolithin A is a gut-microbiota-derived ellagitannin metabolite that can also be administered as a postbiotic compound. Direct Urolithin A exposure is distinct from pomegranate, ellagitannins, ellagic acid, or precursor-food exposure, and branded products are not interchangeable without formulation qualification. Human intervention evidence exists for short-term safety, biomarkers, and selected muscle outcomes, but not for longer human lifespan or general disease treatment.

Research Summary

Preclinical work supports Urolithin A effects on mitophagy, C. elegans lifespan, and rodent muscle/exercise findings; those outcomes are not human longevity results. A first-in-human study evaluated 500 mg and 1,000 mg exposures for short-term safety, bioavailability, and molecular outcomes. A randomized trial in middle-aged adults reported selected muscle strength, exercise-performance, and mitochondrial-biomarker outcomes. These findings do not establish disease prevention, general clinical treatment efficacy, or longer human lifespan.

Research Areas

  • Mitophagy
  • Mitochondrial health
  • Muscle function
  • Exercise performance
  • Human postbiotic research

Safety & Risks

Serious Risks

  • Long-term safety data is limited to the duration of published trials (up to approximately four months in the longest studies available)
  • Individual Urolithin A production from dietary ellagitannins varies substantially by gut microbiome composition — dietary intake of precursor foods does not reliably produce equivalent supplemental exposure

Reported Side Effects

  • Well-tolerated in published Phase I/II trials at evaluated doses
  • Mild gastrointestinal effects reported by some participants
United States
Regulatory status and approved therapeutic use are not established by the sources represented in this record.
United Kingdom
Regulatory status and approved therapeutic use are not established by the sources represented in this record.
Australia
Regulatory status and approved therapeutic use are not established by the sources represented in this record.
Canada
Regulatory status and approved therapeutic use are not established by the sources represented in this record.

Citations & Sources